Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

28
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
28
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

75
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
75
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

6.0K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
6.0K
Dementia l: Introduction01:22

Dementia l: Introduction

35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
Diabetic Neuropathy01:22

Diabetic Neuropathy

59
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
59

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of 5‑Azaindole Inhibitors of O‑GlcNAcase for the Treatment of Alzheimer's Disease and Related Tauopathies.

ACS medicinal chemistry letters·2026
Same author

A sensitive LC‑MS/MS method for the simultaneous quantification of hexosylceramides and hexosylsphingosines, their precursors and metabolites in cells, plasma, and tissue homogenates.

Analytical and bioanalytical chemistry·2026
Same author

Lifelong heat exposure as a potential contributor to Alzheimer's disease resilience.

Journal of Alzheimer's disease : JAD·2026
Same author

Development and validation of a robust UPLC-MS/MS method for the analysis of polyamines in cells, biofluids and tissues.

Journal of pharmaceutical and biomedical analysis·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Related Experiment Video

Updated: May 2, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.1K

Insulin dysfunction and Tau pathology.

Noura B El Khoury1, Maud Gratuze1, Marie-Amélie Papon2

  • 1Département de Psychiatrie et Neurosciences, Faculté de Médecine, Université Laval Québec, QC, Canada ; Axe Neurosciences, Centre Hospitalier de l'Université Laval Québec, QC, Canada.

Frontiers in Cellular Neuroscience
|February 28, 2014
PubMed
Summary
This summary is machine-generated.

Insulin dysfunction, including diabetes mellitus, may accelerate Alzheimer's disease (AD) by promoting Tau hyperphosphorylation. Preclinical studies suggest this link, though experimental artifacts like hypothermia require careful consideration.

Keywords:
Alzheimer's diseaseTau phosphorylationdiabetes mellituskinasesphosphatases

More Related Videos

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

9.8K
Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

8.5K

Related Experiment Videos

Last Updated: May 2, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.1K
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

9.8K
Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

8.5K

Area of Science:

  • Neuroscience
  • Pathology
  • Endocrinology

Background:

  • Alzheimer's disease (AD) is characterized by amyloid plaques and neurofibrillary tangles (NFTs) of hyperphosphorylated Tau protein.
  • NFT pathology correlates with cognitive impairment in AD.
  • Sporadic AD is multifactorial, with insulin dysfunction (e.g., diabetes mellitus) being a potential contributing factor.

Purpose of the Study:

  • To review preclinical studies investigating the link between insulin dysfunction and Tau protein pathogenesis in Alzheimer's disease.
  • To assess the impact of diabetes on Tau pathology, a key factor in AD dementia and memory loss.

Main Methods:

  • Systematic review of preclinical studies (mouse or rat models) examining Tau phosphorylation in the context of insulin dysfunction.
  • Analysis of potential confounding factors such as hypothermia and anesthesia in reported studies.

Main Results:

  • Over 30 studies reported increased Tau phosphorylation in animal models of insulin dysfunction.
  • Insulin dysfunction appears to promote Tau hyperphosphorylation and pathology, both directly and indirectly (e.g., via hypothermia).
  • Many studies lacked detailed reporting on experimental conditions like animal temperature and anesthesia use.

Conclusions:

  • Insulin dysfunction is strongly implicated in promoting Tau hyperphosphorylation and pathology, contributing to Alzheimer's disease.
  • Careful control of experimental conditions, particularly temperature and anesthesia, is crucial for accurate research findings.
  • Further research is needed to elucidate the precise mechanisms linking diabetes and Tau pathogenesis in AD.